*EMBARGOED All research presented at the 2019 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Monday, October 28, 2019, at 8:00 am CDT.

Douglas Wolf, MD, FACG
Douglas Wolf, MD, FACG

Oral 3 Transitioning From Vedolizumab IV to Vedolizumab SC in Patients With Ulcerative Colitis: Results From the VISIBLE Program

Author Insight from Douglas Wolf, MD, FACG, Atlanta Gastroenterology Associates

What’s new here and important for clinicians?

The efficacy and safety of vedolizumab SC formulation in UC patients was evaluated in the Visible Phase 3 program (VISIBLE 1 pivotal study: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy, Visible OLE: Phase 3 Open-Label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn’s Disease)

Patients transitioned from IV to SC vedolizumab treatment at different timepoints: following vedolizumab IV induction (2 or 3 IV vedolizumab infusions) after clinical response was achieved, or during the maintenance phase (at Week 52 on IV vedolizumab every 8 weeks [Q8W] dosing) when the disease was under control.

What do patients need to know?

Our data indicates that patients can transition from IV to SC vedolizumab treatment following either induction or chronic vedolizumab IV (every 8 weeks) treatment with continued efficacy and no new safety signals.

Read the Abstract

Author Contact
Douglas Wolf, MD, FACG, Atlanta Gastroenterology Associates
m4desk [at] aol [dot] com

Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi [dot] org or by phone at 301-263-9000.